Advisors Asset Management, Inc. Intercept Pharmaceuticals, Inc. Transaction History

Advisors Asset Management, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 12, 2021	SELL	$24.48 - $42.47 $94,199 - $163,424	-3,848 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$39.09 - $53.44 $194,785 - $266,291	-4,983 Reduced 56.43%	3,848 $160,000
Q2 2020 Aug 12, 2020	SELL	$46.7 - $92.04 $4,296 - $8,467	-92 Reduced 1.03%	8,831 $423,000
Q1 2020 May 15, 2020	SELL	$48.35 - $118.68 $18,518 - $45,454	-383 Reduced 4.12%	8,923 $562,000
Q4 2019 Feb 14, 2020	SELL	$57.36 - $124.1 $372,438 - $805,781	-6,493 Reduced 41.1%	9,306 $1.15 Million
Q3 2019 Nov 14, 2019	SELL	$58.69 - $80.46 $25,882 - $35,482	-441 Reduced 2.72%	15,799 $1.05 Million
Q2 2019 Aug 14, 2019	SELL	$77.77 - $120.68 $32,119 - $49,840	-413 Reduced 2.48%	16,240 $1.29 Million
Q1 2019 May 15, 2019	BUY	$91.83 - $120.68 $221,310 - $290,838	2,410 Added 16.92%	16,653 $1.86 Million
Q4 2018 Jan 31, 2019	BUY	$85.79 - $126.46 $647,457 - $954,393	7,547 Added 112.71%	14,243 $1.44 Million
Q3 2018 Nov 15, 2018	BUY	$88.49 - $127.55 $592,529 - $854,074	6,696 New	6,696 $846,000

1.04M

30K

5.9K

Ticker ICPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,127,400
Description
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination wit...

Get notified when there are updates to the investment portfolio of Advisors Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Advisors Asset Management, Inc. with notifications on news.